Seasonal influenza vaccine brands include Fluzone/Fluzone Quadrivalent

  • Fluenz Tetra
  • Flumist
  • Flumist Quadrivalent

GlaxoSmithKline

Fluarix, Flulaval and their quadrivalent formulations are split virus inactivated vaccines by GlaxoSmithKline.

  • Fluarix
  • Flulaval
  • Fluarix Tetra

In some countries, Influvac is marketed by Viatris after Upjohn merged with Mylan to create Viatris.

Novartis

  • Optaflu was a trivalent surface antigen inactivated vaccine, the first flu vaccine made in mammalian cell cultures rather than chicken eggs, manufactured by Novartis.

In April 2007, Novartis received a positive opinion supporting European Union approval of Optaflu. In 2017, bioCSL decided to discontinue the usage of the Optaflu brand for commercial reasons.

Sanofi-Aventis

Vaxigrip Tetra and Fluquadri are quadrivalent split virus inactivated vaccines by Sanofi-Aventis.

  • Vaxigrip Tetra
  • Fluquadri
  • Supemtek/Supemtek Tetra

Fluzone

thumb|right|A 5cc vial of Fluzone

Fluzone and its quadrivalent formulation are split virus inactivated vaccines distributed by Sanofi Pasteur mainly in the United States.

Dosage and storage

Fluzone is typically administered in a single dose by intramuscular injection; an intradermal injection is also available. It is presented as a 0.25 ml syringe for pediatric use, as a 0.5 ml syringe for adults and children, as a 0.5 ml vial for adults and children, and as a 5 ml vial for adults and children. This vaccine is intended for people 65 and over, who typically have weakened immune response due to normal aging. The vaccine produces a greater immune response than standard vaccine. According to the CDC,

Supemtek/Supemtek Tetra

Supemtek is a trivalent vaccine.

Supemtek Tetra is a quadrivalent vaccine.

Seqirus

Afluria and its quadrivalent formulation are a split virus inactivated vaccines. Fluad and its quadrivalent formulations are adjuvanted surface antigen inactivated vaccines. Flucelvax and its quadrivalent formulations are surface antigen inactivated vaccines prepared in cell cultures.

Novartis developed the first influenza vaccine, which did not need to be grown in chicken eggs, a cell-based vaccine.

In 2014, CSL Limited obtained Novartis' flu vaccine unit, and transferred it to CSL Subsidiary, bioCSL, named Seqirus.

  • Trivalent
  • Afluria, also marketed as Enzira, Fluvax, and Nilgrip in various different markets
  • Agrippal, also marketed as Begripal, Fluazur, Sandovac, Agriflu, and Chiroflu in various different markets
  • Fluad,
  • Fluad Pediatric, a pediatric vaccine
  • Flucelvax
  • Quadrivalent
  • Afluria Quadrivalent,
  • Fluad Tetra
  • Flucelvax Quad

See also

  • H5N1 vaccine
  • Historical annual reformulations of the influenza vaccine
  • Pandemrix, a historic H1N1 pandemic flu vaccine

References